Impact of docetaxel-based chemotherapy on quality of life of patients with castration-resistant prostate cancer: results from a prospective phase II randomized trial-Reference-Cited by-同舟云学术

Impact of docetaxel-based chemotherapy on quality of life of patients with castration-resistant prostate cancer: results from a prospective phase II randomized trial

Published:2011-05-26 Issue:11 Volume:108 Page:1825-1832
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:

Author:

Caffo Orazio,Sava Teodoro,Comploj Evi,Fariello Annamaria,Zustovich Fable,Segati Romana,Sacco Cosimo,Veccia Antonello,Galligioni Enzo

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1464-410X.2011.10277.x/fullpdf

Reference28 articles.

1. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points;Tannock;J Clin Oncol,1996

2. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study;Kantoff;J Clin Oncol,1999

3. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

4. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N Engl J Med,2004

5. Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomised phase II trial;Caffo;BJU Int,2008

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial;JNCI Cancer Spectrum;2022-07-01

2. Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?;Frontiers in Pharmacology;2022-02-17

3. Comparison of Oncologic Outcomes between Two Alternative Sequences with Abiraterone Acetate and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis;Cancers;2019-12-18

4. Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration-Resistant Prostate Cancer;Value in Health;2017-12

5. The Clinical Efficacy of Enzalutamide in Metastatic Prostate Cancer: Prospective Single-center Study;ANTICANCER RES;2017